Contrast agent-free diffusion weighted- MRI and T1/2 mapping for therapy response monitoring in murine pancreatic ductal adenocarcinoma (PDAC)
Simon Baller1, Irina Heid1, Geoffrey J. Topping2, Katja Steiger3,4, Anna-Maria Schmidmüller2, Felix Harder1, Franz Schilling2, Rickmer Braren1,5
Link to the paper
Research Area C6
Pancreatic ductal adenocarcinoma is one of deadliest cancers worldwide1. Non-invasive (semi)-quantitative MRI methods such as diffusion weighted imaging (DW!) or T1 and T2 mapping are important diagnostic tools for characterization of tissue composition and require no exögenous contrast agent application2,3.
This work aims to investigate the’ use ofthe ADC, Tl and T2 values in a preclinical trial of endogenous murine PDAC treated with the standard therapy protocol Gemcitabine(GEM)/Abraxane.